Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Some statements match the label (e.g., secukinumab as an IL-17A antagonist and labeled indications), but multiple claims about OTC substitutes/supplements are not addressed in the provided FDA label excerpts and are therefore unsupported; several parts are likely off-label/non-label marketing guidance relative to the provided labeling.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a prescription medicine.
Supported as prescription biologic/medication context is implied by label format; however the provided excerpts do not explicitly state 'prescription only.'
Cosentyx is a biologic antibody that targets interleukin-17A (IL-17A).
12.1 Mechanism of Action: secukinumab selectively binds to IL-17A cytokine and inhibits its interaction with the IL-17 receptor; secukinumab is a human IgG1 monoclonal antibody.
Cosentyx targets an immune pathway involved in plaque psoriasis.
1.1 Plaque Psoriasis indication; 12.1 mechanism explains IL-17A targeting for the labeled condition.
Cosentyx targets an immune pathway involved in psoriatic arthritis.
1.2 Psoriatic Arthritis indication; 12.1 mechanism explains IL-17A targeting for the labeled condition.
Cosentyx targets an immune pathway involved in ankylosing spondylitis.
1.3 Ankylosing Spondylitis indication; 12.1 mechanism explains IL-17A targeting for the labeled condition.
Closest alternatives to Cosentyx are other prescription biologics or biosimilars that target related immune pathways and may include IL-17 blockers.
Partially supported only in general via the existence of IL-17A-targeting mechanism in the label; the label excerpts provided do not discuss 'alternatives' or OTC vs prescription alternatives.
Those alternatives are prescription-based, not OTC.
Not addressed in provided label excerpts.
Unsupported Statements
There are no true over-the-counter (OTC) substitutes that work the same way as Cosentyx.
Provided FDA label excerpts do not discuss OTC substitutes or equivalence.
OTC products are not able to replicate the targeted immune mechanism of Cosentyx.
Provided FDA label excerpts do not address OTC products or mechanism replication.
OTC products may support symptom control for skin-related disease, especially for plaque psoriasis, but do not replace Cosentyx’s immune-targeting effect.
Provided FDA label excerpts do not discuss OTC symptom control or replacement of Cosentyx’s effect.
OTC products may make lesions feel better or reduce visible scale.
Not addressed in provided FDA label excerpts.
OTC products do not treat the underlying immune driver the way secukinumab does.
Not addressed in provided FDA label excerpts.
OTC supplements (such as omega-3s, curcumin, or vitamin D) are not equivalent to Cosentyx.
Not addressed in provided FDA label excerpts.
OTC supplements are not considered a substitute for an IL-17A biologic.
Not addressed in provided FDA label excerpts.
Evidence for OTC supplements in psoriasis or arthritis is mixed.
Not addressed in provided FDA label excerpts.
OTC supplements generally do not provide the same degree of disease control as Cosentyx.
Not addressed in provided FDA label excerpts.
Cosentyx targets an immune pathway involved in non-radiographic axial spondyloarthritis (nr-axSpA).
Not explicitly claimed in the provided AI statements; only plaque PsO, PsA, and AS were mentioned.
Contradictions
Low
AI Statement
Cosentyx (secukinumab) is a prescription medicine.
Label Reference
Provided excerpts do not explicitly state 'prescription only,' so contradiction cannot be established; treated here as not contradicted.
Important Omissions
If the response intended to discuss patient safety with Cosentyx, key on-label warnings (e.g., infections/TB evaluation, hypersensitivity) and administration limitations (self-administration limits for pediatrics; IV by healthcare professional) were not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
OTC/supplement substitution guidance is unsupported by the provided label excerpts and could influence treatment decisions; however no direct contraindication or dosing misinformation about Cosentyx was provided in the claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple OTC/supplement equivalence and substitute claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to on-label information present in the provided label excerpts (e.g., labeled indications and mechanism of action). Remove or rephrase OTC/supplement substitution/equivalence claims unless the FDA label provides corresponding language.